Cancer immunotherapy, particularly immune checkpoint inhibitors (ICIs), has transformed the landscape of cancer treatment by enabling the immune system to target and eliminate cancer cells. However, the high cost and complex production of these therapies limit access, especially in low- and middle-income countries (LMICs), where over half of the world’s cancer patients reside. This project addresses these disparities by leveraging plant molecular farming (PMF) as a cost-effective, scalable, and safe alternative for producing immunotherapy drugs locally in Malaysia. Through innovation in biomanufacturing, the initiative aims to expand equitable access to life-saving treatments while aligning with national healthcare and industrial strategies.